 Organosilenium compounds have shown promise as potential treatments for COVID-19. In this study, 10 FDA-approved drugs targeting COVID-19 were used as model pharmacophores to interpret the binding requirements of COVID-19 inhibitors. The antiviral efficacy of the novel organosilenium compounds was assessed by molecular docking against the 6LU7 protein to investigate their possible interactions. The results showed that the organosilenium compounds had strong binding affinity to the virus's primary protease. Additionally, the drug-likeness studies, including Lipinski's rule of five and ADMET properties, were also assessed. The organosilenium compounds manifested solid pharmacokinetic qualities in the ADMET studies, suggesting they may be suitable for further development as effective treatments for COVID-19. This article was authored by Saad Shaban, Ali Abdu, Abdul Rahman G. Alhamzani and others.